News
Positive results for Lynparza plus abiraterone in metastatic prostate cancer
AstraZeneca and MSD have announced positive results for their PARP inhibitor Lynparza (olaparib) in combination with abiraterone as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) patients, with or without homologous recombination repair (HRR) gene mutations.